ArticleAngewandte Chemie (International ed. in English)2025
Saarvienin A-A Novel Glycopeptide with Potent Activity against Drug-Resistant Bacteria.
Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Discovery and Biosynthesis of the Novel Glycotetrapeptide Antibiotic Biffamycin A.Angewandte Chemie (International ed. in English) · 2026Article
- Saarvienin A-A Novel Glycopeptide with Potent Activity against Drug-Resistant Bacteria.Angewandte Chemie (International ed. in English) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A member of a new family of glycopeptides, named saarvienin A, was isolated from a rare actinomycete Amycolatopsis sp. YIM10. Extensive NMR and MS analyses revealed a halogenated peptide core comprising four amino acids cyclized via a ureido linkage with an exocyclic 2-hydroxy-3-(4-hydroxyphenyl)propyl residue connected to a five-sugar/aminosugar chain. Two of the three aminosugars constitute the N-methylated and N,O-dimethylated derivatives of eremosamine (4-epi-vancosamine) that have not been reported in any natural product. Saarvienin A exhibits potent activity against a range of Gram-positive bacteria, effectively overcoming resistance to several frontline antibiotics in clinical isolates. It demonstrates an eight-fold reduction in minimum inhibitory concentrations (MICs) against methicillin-resistant, vancomycin-intermediate, and daptomycin-resistant Staphylococcus aureus compared to vancomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.